Last reviewed · How we verify
Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
This study is aimed to evaluate the efficacy and safety of different doses of radiotherapy combined with sintilimab in locally advanced esophageal squamous cell carcinoma.
Details
| Lead sponsor | Fujian Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 60 |
| Start date | 2024-06-17 |
| Completion | 2027-06 |
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
- chemoradiotherapy （CRT）+sintilimab 1
- CRT+sintilimab 2
Primary outcomes
- progression free survival — 1 years
the time from random assignment in a clinical trial to disease progression or death from any cause - Incidence rate of adverse events — 3 years
The ratio of the number of cases with adverse events to the total number of cases available for evaluation.